ROC analysis showed that anti-ENO1 can differentiate NSCLC patients from normal individuals with AUC (95%CI) of 0.589 (0.539-0.638), sensitivity of 35.1%, specificity of 80.7%, positive predict value (PPV) of 62.0% and negative predictive value (NPV) of 58.0% (Figure 2C). Here, ENO1 is linked to non-small cell lung carcinoma.